Prostate Cancer Patients With Metabolic Syndrome Showed Low Grade Gleason Score When Diagnosed on Biopsy

In a study conducted between January 2005 and January 2011, 354 patients with a PSA value >4 ng/ml or an abnormal digital rectal examination (DRE) underwent transrectal ultrasound-guided prostate biopsy. Of these, 75 patients (21.2%) were diagnosed with metabolic syndrome (MS) according to Adult Treatment Panel III criteria. Prostate cancer was diagnosed in 90 patients (25.4%), with 27 (30%) having MS and 63 (70%) without MS. The study found that while PSA was independently associated with a higher risk of cancer, the presence of MS was not associated with an increased risk of prostate cancer. However, patients with MS had a significantly lower Gleason score (6.63 ± 1.92) compared to those without MS (7.54 ± 1.71, p=0.03). The conclusion of the study was that metabolic syndrome is associated with a lower Gleason score when prostate cancer is diagnosed on transrectal ultrasound-guided prostate biopsy, but this finding needs to be confirmed in a larger multicenter study.